Gill Randeep, Siddiqui Arsalan, Yee Brianna, DiCaro Michael V, Houshmand Nazanin, Tak Tahir
Department of Internal Medicine, Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV 89102, USA.
VA Southern Nevada Healthcare System, 6900 N. Pecos Road, North Las Vegas, NV 89086, USA.
J Cardiovasc Dev Dis. 2024 Sep 18;11(9):290. doi: 10.3390/jcdd11090290.
Hypertrophic cardiomyopathy (HCM) is characterized by excessive growth of myocardial tissue, most commonly due to genetic mutations in sarcomere proteins. This can lead to complications such as heart failure, mitral regurgitation, syncope, arrhythmias, sudden cardiac death, and myocardial ischemia. While we have come a long way in our understanding of the pathophysiology, genetics, and epidemiology of HCM, the past 10 years have seen significant advancements in diagnosis and treatment. As the body of evidence on hypertrophic cardiomyopathy continues to grow, a comprehensive review of the current literature is an invaluable resource in organizing this knowledge. By doing so, the vast progress that has been made thus far will be widely available to all experts in the field. This review provides a comprehensive analysis of the scientific literature, exploring both well-established and cutting-edge diagnostic and therapeutic options. It also presents a unique perspective by incorporating topics such as exercise testing, genetic testing, radiofrequency ablation, risk stratification, and symptomatic management in non-obstructive HCM. Lastly, this review highlights areas where current and future research is at the forefront of innovation in hypertrophic cardiomyopathy.
肥厚型心肌病（HCM）的特征是心肌组织过度生长，最常见的原因是肌节蛋白的基因突变。这可能导致诸如心力衰竭、二尖瓣反流、晕厥、心律失常、心源性猝死和心肌缺血等并发症。虽然我们在对HCM的病理生理学、遗传学和流行病学的理解上已经取得了长足的进步，但在过去10年里，诊断和治疗方面取得了重大进展。随着关于肥厚型心肌病的证据不断增加，对当前文献进行全面综述是整理这些知识的宝贵资源。通过这样做，迄今为止所取得的巨大进展将为该领域的所有专家广泛获取。本综述对科学文献进行了全面分析，探讨了既定的和前沿的诊断及治疗选择。它还通过纳入运动试验、基因检测、射频消融、风险分层和非梗阻性HCM的症状管理等主题，呈现了独特的视角。最后，本综述突出了当前和未来研究在肥厚型心肌病创新前沿的领域。
